Order SLU-PP-332
SLU-PP-332: The “Exercise in a Pill” Under Investigation
Order SLU-PP-332, in recent years, a compelling area of biomedical research has emerge: small molecules or peptides that can mimic aspects of exercise at the cellular level. Among the more promising candidates is SLU-PP-332, sometimes market in capsule form (e.g. 250 µg per capsule) for research applications. While it is not approve for human therapeutic use, SLU-PP-332 has attracted attention due to its ability to activate key regulators of energy metabolism, mitochondrial function, and muscle physiology.
This blog explores what SLU-PP-332 is, how it works, the evidence so far, its potential applications, challenges, and safety considerations.
What Is SLU-PP-332?
Order SLU-PP-332, chemically, SLU-PP-332 is classified as a small molecule agonist of the estrogen-relate receptor (ERR) family, particularly ERRα, ERRβ, and ERRγ (i.e. a pan-ERR agonist).
-
It has measurable binding affinities (EC₅₀ values) in the nanomolar range for ERRα (≈ 98 nM), ERRβ (≈ 230 nM), and ERRγ (≈ 430 nM).
-
The molecular formula is C₁₈H₁₄N₂O₂, and it is also known by the IUPAC name 4-hydroxy-N′-(naphthalen-2-ylmethylene)benzohydrazide.
-
Because ERR receptors are “orphan” nuclear receptors (i.e. their natural/physiological ligand is unclear), synthetic agonists like SLU-PP-332 offer a tool to probe how activating these receptors influences metabolism.
In the laboratory, vendors may supply SLU-PP-332 encapsulate (e.g. 0.25 mg per capsule) for research use only, with disclaimers that it is not for human or diagnostic use.
Thus, at present, SLU-PP-332 is best understood as a research chemical use in preclinical studies, not a drug approve for therapeutic use in humans.
Mechanism of Action: How Does SLU-PP-332 Work?
To appreciate the appeal of SLU-PP-332, it helps to understand how it modulates cellular metabolism. Below is a simplified look:
-
Activation of ERRs
SLU-PP-332 binds to the ligand-binding domain of ERRα, ERRβ, and ERRγ, stabilizing their active conformations and promoting interaction with coactivators (e.g. PGC-1α). -
Mitochondrial biogenesis and function
Activate ERRs upregulate genes involve in mitochondrial biogenesis, oxidative phosphorylation (OXPHOS), electron transport chain components, and other aspects of mitochondrial metabolism.
As a result, cells exhibit enhance respiration, ATP generation, and oxidative capacity, especially in energy-demanding tissues like skeletal muscle. -
Metabolic reprogramming
SLU-PP-332 has been shown (in mice) to boost fatty acid oxidation, reduce fat deposition, and improve glucose handling — all hallmarks of more efficient metabolic states.
It does so without requiring increases in activity or reductions in caloric intake — implying the molecule itself shifts the energy balance. -
Muscle fiber and endurance effects
In skeletal muscle, SLU-PP-332 increases the proportion of oxidative (Type IIa) muscle fibers, augments capillary density, and boosts endurance in animal models.
Researchers have describe this as an “exercise mimetic” effect: it partially recapitulates the molecular changes trigger by aerobic training. -
Tissue-level benefits
Beyond muscle, SLU-PP-332 may influence cardiac tissue (by improving mitochondrial energetics and reducing fibrosis), kidneys (restoring mitochondrial health in aging), and potentially neural tissues (through reduce oxidative stress).
Overall, SLU-PP-332 functions as a lever on the body’s energy machinery, pushing cells toward a more oxidative, efficient, endurance-capable state.
Evidence and Preclinical Studies
Order SLU-PP-332, is still at a preclinical stage, most data comes from animal or cell-line experiments. Some key findings:
-
In diet-induce obese mice, administration of SLU-PP-332 (e.g. 50 mg/kg twice per day over days to weeks) increase energy expenditure, reduced fat mass, improve glucose tolerance, and lower insulin resistance.
-
In normal-weight mice, SLU-PP-332-treate animals ran farther and longer compare to controls — indicative of improve endurance.
-
In models of cardiac stress (e.g. pressure overload), SLU-PP-332 improve ejection fraction, reduce fibrosis, and improve survival.
-
Studies in aging tissues (kidney, muscle) show that SLU-PP-332 could reverse age-associate declines in mitochondrial respiration, lower inflammatory cytokines, and reduce fibrosis.
-
Molecular studies show downstream upregulation of genes like TFAM (mitochondrial transcription factor A), OXPHOS complex genes, and regulators of fatty acid oxidation (e.g. CPT1) with ERR activation.
In sum, the body of preclinical work is promising: SLU-PP-332 appears to deliver measurable metabolic benefits in rodent models, recapitulating parts of what exercise does. However, it is crucial to note that no published human trials exist as of 2025.
Potential Applications & Therapeutic Promise
Although still experimental, SLU-PP-332 has generated excitement for possible future uses:
-
Obesity, Metabolic Syndrome, and Type 2 Diabetes
The capacity to increase energy expenditure, reduce adiposity, and improve insulin sensitivity suggests SLU-PP-332 (or derivatives) might become adjuncts to weight-loss therapy or metabolic disease treatments. -
Muscle Weakness, Sarcopenia, and Aging
In aging populations, where mitochondrial decline and muscle loss occur, an agent that boosts mitochondrial health and oxidative capacity could help preserve strength and function. -
Cardiovascular Disease & Heart Failure
Because the heart is heavily dependent on mitochondrial energetics, SLU-PP-332 might support cardiac function, reverse deleterious remodeling, and reduce fibrosis in certain cardiac pathologies. -
Renal & Organ Aging
Some studies suggest benefits in kidneys and other organs prone to age-related mitochondrial dysfunction. -
Neurodegenerative Disorders
Given the central role of mitochondrial dysfunction in many neurodegenerative diseases, activation of ERRs could have potential in neuroprotection. -
Exercise Alternatives for Immobile Patients
One especially tantalizing concept is delivering “exercise-mimetic” benefits to those who cannot engage in conventional physical activity (e.g. bedridden patients, severe mobility-limited individuals).
Despite the potential, such therapeutic applications must await rigorous human safety and efficacy trials.
Challenges, Unknowns & Safety Considerations
While the data are exciting, many challenges and unanswered questions remain:
-
Lack of human data: No clinical trials in humans exist, so safety, dosing, pharmacodynamics, and long-term effects are unknown.
-
Off-target effects: At high doses, SLU-PP-332 might interact with non-ERR receptors, raising the risk of unrecognized side effects.
-
Pharmacokinetics & bioavailability: The ideal dosing schedule, absorption, metabolism, and half-life remain to be optimized.
-
Tissue specificity: Agonizing ERRs broadly may have unintended consequences in tissues where ERR activity is less well understood.
-
Potential for hypermetabolism: Overactivation could cause hyperthermia, increased heart rate, or metabolic stress.
-
Regulation & ethics: Because SLU-PP-332 is sometimes sold as a “research peptide” or supplement, regulatory oversight is limited — raising concerns about purity, labeling, and misuse.
-
Translation to humans: Results in rodents do not always replicate in human physiology.
-
Cost, manufacturing & formulation: Large-scale, stable, safe production of ERR agonists must be resolve before clinical use.
In short, while the mechanism and preliminary results are promising, the safety margins and translational viability have yet to be establish.
SLU-PP-332 Capsules: What to Know
Although market by some peptide suppliers, SLU-PP-332 capsules are intend for research purposes only, not for human consumption.
Common features of such offerings:
-
Dosage per capsule: Often 0.25 mg (250 µg) or lower amounts (e.g. 250 µg) per capsule.
-
Purity & testing: Reputable suppliers claim chromatographic testing, certificates of analysis (COA), and high purity (e.g. 98–99 %).
-
Intended use: Most sellers explicitly declare they are for in vitro / in vivo research only, not for therapeutic or human use.
-
Storage & handling: As with many peptides, proper storage (often cold, protect from light) is crucial to maintain stability.